Kuldeep Sachdeva

Dr. Kuldeep Sachdeva


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
KJKathiresan Jeyashree
Kathiresan Jeyashree
JTJeromie Thangaraj
Jeromie Thangaraj
KRKiran Rade
Kiran Rade
BMBhavesh Modi
Bhavesh Modi
SSSriram Selvaraju
Sriram Selvaraju
MMManoj Vasant Murhekar
Manoj Vasant Murhekar
Objectives: We verified subnational (state/union territory (UT)/district) claims of achievements in reducing tuberculosis (TB) incidence in 2020 compared with 2015, in India.Design: A community-based survey, analysis of programme data and anti-TB drug sales and utilisation data.Setting: National TB Elimination Program and private TB treatment settings in 73 districts that had filed a claim to the Central TB Division of India for progress towards TB-free status.Participants: Each district was divided into survey units (SU) and one village/ward was randomly selected from each SU. All household members in the selected village were interviewed. Sputum from participants with a history of anti-TB therapy (ATT), those currently experiencing chest symptoms or on ATT were tested using Xpert/Rif/TrueNat. The survey continued until 30 Mycobacterium tuberculosis cases were identified in a district.Outcome measures: We calculated a direct estimate of TB incidence based on incident cases identified in the survey. We calculated an under-reporting factor by matching these cases within the TB notification system. The TB notification adjusted for this factor was the estimate by the indirect method. We also calculated TB incidence from drug sale data in the private sector and drug utilisation data in the public sector. We compared the three estimates of TB incidence in 2020 with TB incidence in 2015.Results: The estimated direct incidence ranged from 19 (Purba Medinipur, West Bengal) to 1457 (Jaintia Hills, Meghalaya) per 100 000 population. Indirect estimates of incidence ranged between 19 (Diu, Dadra and Nagar Haveli) and 788 (Dumka, Jharkhand) per 100 000 population. The incidence using drug sale data ranged from 19 per 100 000 population in Diu, Dadra and Nagar Haveli to 651 per 100 000 population in Centenary, Maharashtra.Conclusion: TB incidence in 1 state, 2 UTs and 35 districts had declined by at least 20% since 2015. Two districts in India were declared TB free in 2020.

20 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYing Jiang
Ying Jiang
KSKuldeep Sachdeva
Kuldeep Sachdeva
CGChris N. Goulbourne
Chris N. Goulbourne
MBMartin John Berg
Martin John Berg
JPJames Peddy
James Peddy
RNRalph A. Nixon
Ralph A. Nixon
Endosomal system dysfunction within neurons is a prominent early feature of Alzheimer’s disease (AD) pathology. Multiple AD risk factors are regulators of endocytosis and are known to cause hyper-activity of the early-endosome small GTPase rab5, resulting in neuronal endosomal pathway disruption and cholinergic neurodegeneration. Adaptor protein containing Pleckstrin homology domain, Phosphotyrosine binding domain, Leucine zipper motif (APPL1), an important rab5 effector protein and signaling molecule, has been shown in vitro to interface between endosomal and neuronal dysfunction through a rab5-activating interaction with the BACE1-generated C-terminal fragment of amyloid precursor protein (APP-βCTF), a pathogenic APP fragment generated within endosomal compartments. To understand the contribution of APPL1 to AD-related endosomal dysfunction in vivo , we generated a transgenic mouse model over-expressing human APPL1 within neurons (Thy1-APPL1 mice). Strongly supporting the important endosomal regulatory roles of APPL1 and their relevance to AD etiology, Thy1-APPL1 mice develop enlarged neuronal early endosomes and increased synaptic endocytosis due to increased rab5 activation. We demonstrated pathophysiological consequences of APPL1 overexpression, including functional changes in hippocampal long-term potentiation (LTP) and long-term depression (LTD), degeneration of large projection cholinergic neurons of the basal forebrain, and impaired hippocampal-dependent memory. Our evidence shows that neuronal APPL1 elevation modeling its functional increase in the AD brain induces a cascade of AD-related pathological effects within neurons, including early endosome anomalies, synaptic dysfunction, and selective neurodegeneration. Our in vivo model highlights the contributions of APPL1 to the pathobiology and neuronal consequences of early endosomal pathway disruption and its potential value as a therapeutic target. Significance Statement: Neuronal endosome dysfunction appears early in Alzheimer’s disease (AD) and is linked to memory loss. Genes and risk factors associated with AD often increase rab5 activity, a protein that disrupts endosomal signalling when hyperactivated. APPL1, a key rab5 partner, worsens this dysfunction via its interaction with APP-βCTF, a protein fragment associated with AD. To explore APPL1’s role, we created a genetically modified mouse that overexpresses APPL1 in neurons. This model provides the first in vivo evidence that APPL1 overexpression triggers key AD-like effects: rab5 hyperactivation, enlarged early endosomes, loss of cholinergic neurons, reduced synaptic plasticity in memory-related brain regions, and memory deficits. These findings highlight APPL1’s role in AD pathogenesis and its potential as a therapeutic target.

1 January 2021 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
KSKuldeep Sachdeva
Kuldeep Sachdeva

23 October 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YCYun-juan Chang
Yun-juan Chang
PSPhilip H. Stavrides
Philip H. Stavrides
HPHarshitha Pidikiti
Harshitha Pidikiti
KIKyrillos W. Ibrahim
Kyrillos W. Ibrahim
JLJu-hyun Lee
Ju-hyun Lee
Stephen GinsbergStephen Ginsberg
Stephen Ginsberg
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder where early molecular disruptions precede overt pathology and neuronal loss. To identify transcriptional events that bias neurons toward degeneration or resilience, we reanalyzed two single-nucleus RNA-sequencing datasets originally generated to investigate glial responses in an established AD murine model. Methods: Using a neuron-centric analytical framework, excitatory neuronal cells were selected for downstream bioinformatics involving unsupervised clustering, trajectory inference, and functional analyses. Results: This approach revealed neuronal heterogeneity and enabled reconstruction of inferred transcriptional trajectories in a discovery dataset. Three distinct neuronal states along an inferred continuum from stability to degeneration were identified: a homeostatic state, a transitional stress-adaptive state, and an AD-associated state. The transitional state was positioned near a trajectory bifurcation point, indicating divergence toward either partial resilience or an AD-like trajectory. Differential gene expression and pathway analyses revealed RNA-processing dysregulation in the transitional state, suggesting that early alterations in RNA metabolism may play a key role in biasing neurons toward pathological progression. The homeostatic and transitional neuronal states were independently validated, whereas the AD-associated state was not, potentially reflecting differences in brain-region sampling, sequencing strategies, and/or the transient nature of the disease-associated state. Conclusions: This study identified distinct neuronal transcriptional states and inferred trajectories associated with AD-related vulnerability, highlighting RNA-processing dysfunction as a candidate mechanistic contributor of neuronal fate divergence in AD progression. This work provides a foundation for future studies to define cell-type-specific RNA dysregulation in relevant animal models and human postmortem brain tissues to determine whether early RNA-metabolic imbalance and upstream signaling drivers can serve as mechanistic biomarkers or therapeutic intervention points in AD.